CD137, Fc Chimera, Recombinant, Rat, aa24-188 (4-1BB, TNFRSF9, ILA)

4-1BB, also known as CD137 and TNFRSF9, is an ~30kD transmembrane glycoprotein in the TNF receptor superfamily. 4-1BB functions in the development and activation of multiple immune cells (1). Mature rat consists of a 166 amino acid (aa) extracellular domain (ECD) with four TNFR cysteine-rich repeats, a 21aa transmembrane segment, and a 48aa cytoplasmic domain. Within the ECD, rat 4-1BB shares 60% and 79% aa sequence identity with human and mouse 4-1BB, respectively. 4-1BB is expressed as a disulfideпїЅlinked homodimer on various populations of activated T cells including CD4+, CD8+, memory CD8+, NKT, and regulatory T cells (2-5) as well as on myeloid and mast cell progenitors, dendritic cells, mast cells, and bacterially infected osteoblasts (6-9). It binds with high affinity to the transmembrane 4-1BB Ligand/TNFSF9 which is expressed on antigen presenting cells and myeloid progenitor cells (6, 10). This interaction co-stimulates the proliferation, activation, and/or survival of the 4-1BB expressing cell (2-5, 10). It can also enhance the activationпїЅinduced cell death of repetitively stimulated T cells (10). Mice lacking 4пїЅ1BB show augmented T cell activation, perhaps due to its absence on regulatory T cells (11). 4пїЅ1BB can associate with OX40 on activated T cells, forming a complex that responds to either ligand and inhibits Treg and CD8+ T cell proliferation (12). Reverse signaling through 4пїЅ1BB Ligand inhibits the development of dendritic cells, B cells, and osteoclasts (6, 9) but supports mature dendritic cell survival and co-stimulates the proliferation and activation of mast cells (7, 8). 4-1BB activation enhances CD8+ T cell and NK cell mediated anti-tumor immunity (13). It also contributes to the development of inflammation in high fat dietпїЅinduced metabolic syndrome (14). Soluble forms of 4-1BB and 4-1BB Ligand circulate at elevated levels in the serum of rheumatoid arthritis and hematologic cancer patients, respectively (15, 16).\n\nSource:\nRecombinant protein corresponding to aa24-188 from rat 4-1BB/TNFRSF9 Fc Chimera, NS0-derived.\n\nMolecular Weight:\n~60-65kD\n\nEndotoxin:\n<0.01EU/1ug (LAL method)\n\nStorage and Stability:\nLyophilized powder may be stored at -20 degrees C. Stable for 12 months at -20 degrees C. Reconstitute with PBS. Aliquot to avoid repeated freezing and thawing. Store at -20 degrees C. Reconstituted product is stable for 12 months at -20 degrees C. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap. Further dilutions can be made in assay buffer.

Prices direct from United States Biological

Quick response times

Exclusive Biosave savings/discounts

SPECIFICATIONS

Catalog Number

145778

Size

50ug

Form

Supplied as a lyophilized powder in PBS. BSA free. Reconstitute in 100ug/ml PBS.

Purity

~95% (SDS-PAGE)

References

1. Wang, C. et al. (2009) Immunol. Rev. 229:192. 2. Wen, T. et al. (2002) J. Immunol. 168:4897. 3. Pulle, G. et al. (2006) J. Immunol. 176:2739. 4. Zheng, G. et al. (2004) J. Immunol. 173:2428. 5. Kim, D. et al. (2008) J. Immunol. 180:2062. 6. Lee, S. et al. (2008) Nat. Immunol. 9:917. 7. Choi, B.K. et al. (2009) J. Immunol. 182:4107. 8. Nishimoto, H. et al. (2005) Blood 106:4241. 9. Saito, K. et al. (2004) J. Biol. Chem. 279:13555. 10. Alderson, M.R. et al. (1994) Eur. J. Immunol. 24:2219. 11. Lee, S. et al. (2005) J. Immunol. 174:6803. 12. Ma, B.Y. et al. (2005) Blood 106:2002. 13. Choi, B.K. et al. (2010) J. Immunol. 185:1404. 14. Kim, C. et al. (2011) Diabetes 60:3159. 15. Michel, J. et al. (1998) Eur. J. Immunol. 28:290. 16. Salih, H.R. et al. (2001) J. Immunol. 167:4059.